Physician profile

Robert Johnston Lingle

Cardiovascular Disease · Humble, TX

NPI 1992931133

$10,173.83

in general payments reported to CMS, 2019-2025

45 companies · $1,577 in 2025

The $1,577 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,801.20

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $1,164.61 2020-2025 Aveir, Assurity, Ensite Precision
Boston Scientific Corporation $1,089.13 2019-2025 Watchman Flx, Watchman Access System
Novartis Pharmaceuticals Corporation $690.18 2019-2025
Merck Sharp & Dohme LLC $636.94 2021-2025 Verquvo, Steglatro, Steglujan
Heartflow, INC. $578.71 2019-2025
Bard Peripheral Vascular, INC. $525.01 2019-2022
E.R. Squibb & Sons, L.L.C. $485.78 2019-2025 Eliquis, Camzyos
Janssen Pharmaceuticals, INC $424.57 2019-2023 Xarelto
Amarin Pharma, INC. $374.45 2019-2022
Impulse Dynamics (USA) INC. $355.45 2021-2023 Optimizer
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $267.39 2020-2024 Lifevest
Cvrx, INC. $264.92 2021-2024 Barostim Neo System
Kestra Medical Technology Services, INC. $249.39 2024-2025 Assure Wcd
Astrazeneca Pharmaceuticals LP $232.82 2019-2025 Farxiga, Wainua
Pfizer INC. $232.48 2019-2024
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $212.49 2019-2025 Jardiance
Novo Nordisk INC $212.15 2019-2025 Ozempic, Wegovy, Rybelsus
Amgen INC. $204.14 2019-2025 Repatha, Repatha
Astellas Pharma US INC $202.68 2019-2020
Tactile Systems Technology INC $168.29 2020-2022
Biotronik INC. $156.97 2019
Bridgebio Pharma, INC. $150.74 2025 Attruby
Esperion Therapeutics, INC. $143.03 2021-2025 Nexletol
Kowa Pharmaceuticals America, INC. $132.09 2019-2022
Sanofi-Aventis U.S. LLC $126.84 2019-2024
Cardiovascular Systems INC. $108.33 2019-2020
Canon Medical Systems USA, INC. $98.83 2023 Pet-Ct Scanner
Actelion Pharmaceuticals US, INC. $85.02 2019-2024 Uptravi, Opsumit
Atricure, INC. $77.59 2022-2024
Alnylam Pharmaceuticals INC. $76.77 2021-2022
Bolton Medical INC $65.63 2020
Regeneron Pharmaceuticals, INC. $64.92 2019-2025 Evkeeza
Kiniksa Pharmaceuticals International, Plc $51.53 2024 Arcalyst
Bayer Healthcare Pharmaceuticals INC. $38.04 2025
Biosense Webster, INC. $34.11 2023 Carto 3
Biohaven Pharmaceutical Holding Company LTD. $26.92 2022
Regeneron Healthcare Solutions, INC. $25.17 2019
Resmed Corp $25.09 2022
Ge Healthcare $22.45 2022
Medtronic, INC. $18.92 2022
Azurity Pharmaceuticals, INC. $17.11 2025 Edarbi
Lexicon Pharmaceuticals, INC. $15.01 2023 Inpefa
Lemaitre Vascular, INC. $13.96 2019
Arbor Pharmaceuticals, INC. $13.79 2019
Becton, Dickinson and Company $13.39 2024 Rotarexs 6 F X 135 Cm

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert Johnston Lingle

$10,173.83

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbott Laboratories
Context
The $1,577 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/90553/robert-johnston-lingle

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.